The incidents of children dying in Uzbekistan after consuming cough medicine made by an Indian company and the discovery of toxic ingredients in eye drops are just a few examples of the potential dangers of counterfeit medicines.
New Delhi : The recent cancellation of licenses of 18 pharma companies by the regulatory body of the Union Ministry of Health, DCGI, on charges of manufacturing fake medicines is a serious matter. The quality test failure of 48 widely used medicines, ranging from heart medications, diabetes, blood pressure to multivitamins, with adulterated ingredients is alarming. It is disturbing that these medicines are commonly used by people who rely on them for their health and well-being.
The incidents of children dying in Uzbekistan after consuming cough medicine made by an Indian company and the discovery of toxic ingredients in eye drops are just a few examples of the potential dangers of counterfeit medicines. The center's action to judge the quality of medicines is commendable, but the recent findings reveal that more needs to be done to ensure the safety and effectiveness of drugs in the market.
The list of failed drugs includes commonly prescribed medicines such as anti-diabetic glimepiride and metformin, along with telmisartan used for high blood pressure, and vitamins such as vitamin C, vitamin B12, folic acid, amoxicillin, and vitamin D3 tablets. The fact that these medicines have been used widely raises concerns about the potential harm they may have caused to patients.
It is reassuring to note that some pharma companies have come forward to clear the air around the failed batch of medicines. However, it is crucial that the Ministry of Health takes strong action against the pharma companies found guilty of manufacturing fake medicines. It is essential to maintain the integrity of the drug supply chain and ensure that patients receive safe and effective medicines.
DCGI officials conducted surprise visits to the offices of 76 drug manufacturing companies in 20 states, and the cancellation of licenses of 18 pharma companies for manufacturing fake drugs shows the commitment to ensuring the safety of medicines. We urge the government to continue such efforts to ensure the safety and effectiveness of medicines in the market, and strict action should be taken against those found guilty of violating quality standards. The health and well-being of the citizens should always be the top priority.
New Delhi : The recent cancellation of licenses of 18 pharma companies by the regulatory body of the Union Ministry of Health, DCGI, on charges of manufacturing fake medicines is a serious matter. The quality test failure of 48 widely used medicines, ranging from heart medications, diabetes, blood pressure to multivitamins, with adulterated ingredients is alarming. It is disturbing that these medicines are commonly used by people who rely on them for their health and well-being.
The incidents of children dying in Uzbekistan after consuming cough medicine made by an Indian company and the discovery of toxic ingredients in eye drops are just a few examples of the potential dangers of counterfeit medicines. The center's action to judge the quality of medicines is commendable, but the recent findings reveal that more needs to be done to ensure the safety and effectiveness of drugs in the market.
The list of failed drugs includes commonly prescribed medicines such as anti-diabetic glimepiride and metformin, along with telmisartan used for high blood pressure, and vitamins such as vitamin C, vitamin B12, folic acid, amoxicillin, and vitamin D3 tablets. The fact that these medicines have been used widely raises concerns about the potential harm they may have caused to patients.
It is reassuring to note that some pharma companies have come forward to clear the air around the failed batch of medicines. However, it is crucial that the Ministry of Health takes strong action against the pharma companies found guilty of manufacturing fake medicines. It is essential to maintain the integrity of the drug supply chain and ensure that patients receive safe and effective medicines.
DCGI officials conducted surprise visits to the offices of 76 drug manufacturing companies in 20 states, and the cancellation of licenses of 18 pharma companies for manufacturing fake drugs shows the commitment to ensuring the safety of medicines. We urge the government to continue such efforts to ensure the safety and effectiveness of medicines in the market, and strict action should be taken against those found guilty of violating quality standards. The health and well-being of the citizens should always be the top priority.
Post a Comment